Boston Scientific disclosed that a cyber‑security breach discovered on Aug. 25 temporarily knocked out key IT systems, halting order processing and disrupting parts of its global operations. The attack forced the company to pause shipments and slowed manufacturing at several sites, prompting concerns that the incident could dent its upcoming financial results. In a fresh update, the firm announced that all sterilization facilities are now fully operational and back to processing products, and that manufacturing has resumed at most of its plants worldwide. Additional production capacity is being brought online as the company continues to restore its digital infrastructure. While the breach highlighted vulnerabilities in the company’s data networks, Boston Scientific says the swift recovery of critical facilities limits the long‑term impact on revenue. Investors are watching closely as the company works to fully normalize its supply chain and reassure customers that product quality and safety remain uncompromised. The episode serves as a reminder of how cyber threats can ripple through the medical‑device industry, affecting everything from order fulfillment to quarterly earnings.
Read moreThe Zhangjiang Medicine Valley International Innovation Conference gathered top scientists, industry leaders and policymakers to map out China’s fast‑moving stem‑cell sector. Academician Gao Shaorong opened the event by declaring that pluripotent stem cells are now the cornerstone of China’s regenerative‑medicine strategy, shifting the country from “catch‑up” to a leadership role. A major focus was the impact of the new “818” and “828” regulations. Experts explained how these rules will streamline approvals, raise safety standards and open fresh funding streams for cell‑therapy firms, while also warning of compliance pitfalls. Highlights included: • Exosome research for anti‑aging products, presented by Russian Academy member Zhang Dan, pointing to next‑generation skin and health boosters. • A full‑chain roadmap for turning lab discoveries into market‑ready stem‑cell therapies, outlined by President Liu Zhongmin. • Insights into the booming “longevity economy,” where stem‑cell tech meets age‑defying business models, shared by PLA General Hospital’s Wang Xiaoning. • Data‑driven precision medicine, with biochip leader Wang Weiye stressing the power of biological‑sample analytics. • Progress on mesenchymal stem‑cell drugs, tissue regeneration, universal organ‑transplant strategies, and heart‑repair cells derived from pluripotent stem cells. International voices, such as Singapore’s A*STAR researcher So Boon Seng, added perspectives on mitochondrial rescue for metabolic diseases. The conference underscored a four‑track ecosystem—policy, research, clinical translation, and industry—aimed at turning stem‑cell breakthroughs into everyday health solutions under China’s “Healthy China” agenda.
Read more